Navigation Links
Ambit Biosciences Announces Third Quarter 2013 Operating Results
Date:11/7/2013

f Ambit's drug development programs, including the submission of regulatory filings and planned discussions with regulatory bodies, plans regarding future clinical trials of quizartinib and Ambit's other drug candidates, the progress and expected timing of clinical trials, the presentation of data from clinical trials, the clinical benefits to be derived from quizartinib and Ambit's other drug candidates, the regulatory approval path for quizartinib, the strength of Ambit's balance sheet and adequacy of cash on hand, and Ambit's financial guidance.. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Words such as  "plans," "expects," "anticipates," "hopes", "may," "will," "goal," "potential" and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon Ambit's current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, which include, without limitation, risks associated with the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics, and in the endeavor of building a business around such drugs. These and other risks concerning Ambit's programs are described in additional detail in Ambit's SEC filings. All forward-looking statements contained in this press release speak only as of the date on which they were made. Ambit undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.

  Ambit Biosciences CorporationSelected Financial Information Condensed Consolidated Statements of Operations(unaudited, in thou
'/>"/>

SOURCE Ambit Biosciences
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Ambit Announces Participation At 12th Annual BIO Investor Forum
2. Ambit Announces Participation At The BioCentury NewsMakers in the Biotech Industry Conference
3. Ambit Announces Presentation of Results from Phase 2 ACE Study of Quizartinib in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) at the Annual Meeting of the American Society of Clinical Oncology
4. Ambit Biosciences Files Registration Statement for Proposed Initial Public Offering
5. APAC Stem Cell Research & Therapy Market a “Growth Engine” for Region’s Scientific Ambitions Says A New Market Research Report at ReportsnReports.com
6. Astellas and Ambit Announce Data Presentations Highlighting Quizartinib at the American Society of Hematology 54th Annual Meeting
7. Ambit Biosciences to Present at Two Upcoming Investor Conferences
8. Ambit and Astellas Announce Results From Multiple Quizartinib Presentations at the 53rd Annual Meeting of the American Hematology Society
9. Ambit Biosciences Names Michael A. Martino President and Chief Executive Officer
10. Pressure BioSciences, Inc. Reports Third Quarter 2013 Financial Results and Provides Business Update
11. Juneau Biosciences Names Dr. Dinesh Patel to Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/28/2015)... , May 28, 2015 RXi Pharmaceuticals Corporation ... discovering and developing innovative therapeutics, primarily in the areas ... a public offering of 26 million units at a ... gross proceeds of approximately $10.4 million. Each unit consists ... 13-month overallotment purchase right to purchase 0.50 of a ...
(Date:5/28/2015)... 2015 The Fertility Centers of New ... Danielle Vitiello has taken on a new and expanded ... will provide guidance, leadership, oversight and quality assurance for ... Vitiello among our team of experienced reproductive endocrinologists,” said ... A. Hill, M.D. “Her expertise and compassionate, individualized care ...
(Date:5/28/2015)... May 28, 2015 American Process ... (Oak Ridge, TN) recently signed a joint ... printing plastic resins using nanocellulose, a rapidly emerging ... 3D printing is the limited number of feedstock ... mechanical strength to printed parts for load bearing ...
(Date:5/27/2015)... , May 27, 2015  The Companion Diagnostics ... understanding and unprecedented access to the partnering deals ... healthcare companies during 2014. Using these ... into the partnering activities of the past year. ... the partnering and alliances deals announced worldwide.The initial ...
Breaking Biology Technology:RXi Pharmaceuticals Announces $10 Million Public Offering of Common Stock and Warrants 2RXi Pharmaceuticals Announces $10 Million Public Offering of Common Stock and Warrants 3Danielle Vitiello, MD of Fertility Centers of New England, Named New Medical Director 2American Process Inc. Announces Partnership with Oak Ridge National Laboratory to Make 3D Printing Plastic Resins Stronger and More Sustainable 2American Process Inc. Announces Partnership with Oak Ridge National Laboratory to Make 3D Printing Plastic Resins Stronger and More Sustainable 3Companion Diagnostics Deals and Alliances of 2014 2
... Dec. 17, 2008 Senomyx, Inc.,(Nasdaq: ... proprietary taste receptor,technologies to discover and develop novel ... industries, announced today that Kent Snyder,the Company,s President ... Financial and Business Officer, will present a corporate ...
... acquisition price will be $215 million , , ... infectious disease , , CARLSBAD, Calif. ... ISIS ) and Abbott (NYSE: ABT ) ... remaining equity ownership in Ibis Biosciences, Inc., an Isis subsidiary, for ...
... Simple , ... (PRWEB) December 17, 2008 -- Facilitating ... is the modern protocol analyzer, now updated to effortlessly examine not ... and a telephone modem, but also the interface between the device ...
Cached Biology Technology:SENOMYX TO WEBCAST CORPORATE PRESENTATION AT THE 11TH ANNUAL NEEDHAM GROWTH STOCK CONFERENCE 2Abbott Exercises Its Option to Acquire Ibis Biosciences, a Subsidiary of Isis 2Abbott Exercises Its Option to Acquire Ibis Biosciences, a Subsidiary of Isis 3Abbott Exercises Its Option to Acquire Ibis Biosciences, a Subsidiary of Isis 4Abbott Exercises Its Option to Acquire Ibis Biosciences, a Subsidiary of Isis 5Newly Available To Medical Device Manufacturers - Bluetooth Testing Equipment 2Newly Available To Medical Device Manufacturers - Bluetooth Testing Equipment 3
(Date:4/20/2015)... The announcement comes as demand for fire vault ... Ireland,s foremost records management company, has secured ... impressive track record of clients within the first 12 months, ... sector in Dubai . As a result, ... a further eight staff members at its Irish headquarters. The ...
(Date:4/14/2015)... , April 14, 2015  HYPR Corp. ... Online (FIDO ® ) Alliance tm , an ... FIDO members commit to share technology and collaborate ... that are interoperable, more secure and private, and ... biometric identity verification that protects sensitive user information ...
(Date:4/13/2015)... NEW YORK , April 13, 2015 /PRNewswire/ ... study by TechSci Research, "Global Biometrics Market Forecast & ... to register a CAGR of around 14% till ... various governments for large scale implementation and review ... technology and launch of new products with greater ...
Breaking Biology News(10 mins):Glenbeigh Records Management Wins Contract With Dubai Islamic Bank 2Glenbeigh Records Management Wins Contract With Dubai Islamic Bank 3HYPR Corp. Joins the FIDO Alliance 2HYPR Corp. Joins the FIDO Alliance 3Global Biometrics Market to Cross US$ 21 Billion by 2020: TechSci Research 2
... epilepsy: the disease affects the very core of our ... seizures throughout the body or in parts of it. ... The causes are still only partially understood but in some ... diseases have been implicated. Epilepsy is not confined to ...
... and Society for Vascular Surgery jointly will launch PRESERVEthe ... of inferior vena cava (IVC) filters and related follow-up ... the IVC Filter Study Group Foundationare direct actions taken ... the possibility that retrievable IVC filters could move or ...
... asked the federal government for a license to perform a ... these trees has a slightly different composition, meaning that it ... more environmentally friendly manner. One of the aims of the ... realistic outdoor conditions. Another aim will be to expose the ...
Cached Biology News:Cats and humans suffer from similar forms of epilepsy 2Medical societies to launch large-scale study on vein filter use 2VIB applies for second poplar field trial 2